Deramiocel
Muscular Disorders, Atrophic
Capricor Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Muscular Disorders, Atrophic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enobosarm GTx | Phase 3 | B |
Ataluren PTC Therapeutics | Phase 3 | B |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
Allogeneic Cardiosphere-Derived Cells Capricor Inc. | Phase 2 | B |
Semaglutide Biophytis | Phase 2 | CCC |
bio101 Biophytis | Phase 2 | CCC |
Delpacibart Zotadirsen | D | |
Srk-015 Scholar Rock, Inc. | Phase 3 | NR |
Same molecule, other indications
Deramiocel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →